Literature DB >> 12087577

Can glomerular mRNAs in human type 1 diabetes be used to predict transition from normoalbuminuria to microalbuminuria?

Sharon G Adler1, Shin-Wook Kang, Stella Feld, Dae Ryong Cha, Lilly Barba, Liliane Striker, Gary Striker, Bruce L Riser, Janine LaPage, Cynthia C Nast.   

Abstract

BACKGROUND: mRNAs of pathogenetic importance in the development of diabetic nephropathy were measured in subjects with type 1 diabetes to determine whether these might be used to predict progression from normoalbuminuria to microalbuminuria. We proposed that conversion from normoalbuminuria to microalbuminuria would be most likely in subjects whose connective tissue growth factor (CTGF) and collagen mRNAs were above the 95% confidence interval (CI) for live renal donors and within the 95% CI for subjects with abnormal albuminuria.
METHODS: Glomerular CTGF, collagen alpha2(IV), and control glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNAs were measured in microdissected glomeruli from living renal donors (n = 10), and subjects with normoalbuminuria (n = 12), microalbuminuria (n = 5), and overt proteinuria (n = 6).
RESULTS: After 44 +/- 2 months of follow-up, one subject converted from normoalbuminuria to microalbuminuria. Although the data are limited, progression from normoalbuminuria to microalbuminuria occurred in the only normoalbuminuric subject whose mRNA levels were above the live renal donors' 95% CI for CTGF and collagen alpha2(IV) and within the 95% CI of subjects with abnormal albuminuria. No clinical or histopathologic finding distinguished the progressor from the nonprogressors at the time of biopsy.
CONCLUSION: This case report provides proof-of-principle that a panel of glomerular mRNA markers chosen because of their pathogenetic relevance may be useful adjuncts to albuminuria and histology in predicting clinical stability or clinical progression in diabetic nephropathy. Copyright 2002 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12087577     DOI: 10.1053/ajkd.2002.33928

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  10 in total

1.  CCN-2 is up-regulated by and mediates effects of matrix bound advanced glycated end-products in human renal mesangial cells.

Authors:  Xiaoyu Wang; Susan V McLennan; Stephen M Twigg
Journal:  J Cell Commun Signal       Date:  2011-06-02       Impact factor: 5.782

2.  The time has come to target connective tissue growth factor in diabetic complications.

Authors:  S M Twigg; M E Cooper
Journal:  Diabetologia       Date:  2004-05-28       Impact factor: 10.122

3.  Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria.

Authors:  Sharon G Adler; Sherwyn Schwartz; Mark E Williams; Carlos Arauz-Pacheco; Warren K Bolton; Tyson Lee; Dongxia Li; Thomas B Neff; Pedro R Urquilla; K Lea Sewell
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-03       Impact factor: 8.237

4.  Mastering a mediator: blockade of CCN-2 shows early promise in human diabetic kidney disease.

Authors:  Stephen M Twigg
Journal:  J Cell Commun Signal       Date:  2010-10-19       Impact factor: 5.782

5.  Balanced regulation of the CCN family of matricellular proteins: a novel approach to the prevention and treatment of fibrosis and cancer.

Authors:  Bruce L Riser; Jeffrey L Barnes; James Varani
Journal:  J Cell Commun Signal       Date:  2015-12-23       Impact factor: 5.782

Review 6.  Prevalence and Management of Diabetic Nephropathy in Western Countries.

Authors:  Bancha Satirapoj; Sharon G Adler
Journal:  Kidney Dis (Basel)       Date:  2015-05-01

7.  BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression.

Authors:  Tamara Turk; Jan Willem Leeuwis; Julia Gray; Suzy V Torti; Karen M Lyons; Tri Q Nguyen; Roel Goldschmeding
Journal:  J Histochem Cytochem       Date:  2009-03-02       Impact factor: 2.479

8.  Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease.

Authors:  Qingjian Wang; William Usinger; Blake Nichols; Julia Gray; Leon Xu; Todd W Seeley; Mitch Brenner; Guangjie Guo; Weihua Zhang; Noelynn Oliver; Al Lin; David Yeowell
Journal:  Fibrogenesis Tissue Repair       Date:  2011-02-01

Review 9.  Comprehensive approach to diabetic nephropathy.

Authors:  Bancha Satirapoj; Sharon G Adler
Journal:  Kidney Res Clin Pract       Date:  2014-09-10

Review 10.  Tubulointerstitial Biomarkers for Diabetic Nephropathy.

Authors:  Bancha Satirapoj
Journal:  J Diabetes Res       Date:  2018-02-08       Impact factor: 4.011

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.